Unichem Labs Q2 FY26: Consolidated Loss Rs 11.89 Cr from EU Fine Interest

Exceptional itemResults restatedNet loss reportedRevenue declinedResults View source PDF Explain this filing

UNICHEMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹478.50

prior close

₹476.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%-1.4% vs market

Pharmaceuticals peers, median of 157sector+0.8%-1.3% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.1

15m

-0.1

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4+0.9-1.4+0.8-1.3

Next day

-2.6+0.8-3.5+0.5-3.1

-2.0+0.7-2.7+0.4-2.4

-1.1+1.3-2.5+0.6-1.7

-0.7+0.5-1.2-0.1-0.6

+0.8+0.4+0.4-0.6+1.4

-2.7-1.5-1.2-1.2-1.5

15d

-5.7-2.4-3.3-1.8-4.0

-4.7-4.4-0.3-2.6-2.1

-13.4-7.2-6.2-5.4-8.0

-19.6-5.0-14.7-5.7-13.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q2 and H1 FY26 unaudited results. Consolidated revenue grew to Rs 578.96 cr (Q2) from Rs 507.36 cr; H1 at Rs 1,105.56 cr. PAT swung to a loss of Rs 11.89 cr Q2 and Rs 22.36 cr H1 from profits, due to Rs 58.26 cr exceptional interest charge on the Euro 19.55 million EU Commission fine, fully settled on 28 Oct 2025. Standalone H1 loss Rs 41.78 cr. Comparatives restated. Auditors gave unmodified opinion.

Likely market impact

One-time EU fine interest caused swing to consolidated loss, but underlying operations improved. Standalone revenue declined. EU liability now fully settled.